Allergan Posts Flat Q3 Profit, Lifts Low End Of Earnings Outlook

(RTTNews.com) – Multi-specialty health care company Allergan Inc. (AGN) on Tuesday reported a profit for the third quarter that was flat with last year despite higher sales of ...

Orthofix forks over $32M to settle kickback case

By Damian Garde Orthofix International ($OFIX) has settled the kickback case against its Blackstone Medical subsidiary, paying $32 million to resolve charges that the company paid ...

CryoLife revenue jumped in Q3

The company’s sales gains came, in part, from M&A, but a growing surgical sealant business also helped By Mark Hollmer CryoLife ($CRY) celebrates a robust 2012 third quarter ...

Stryker CEO touts paradigm shift

Kevin Lobo says the devicemaker is looking at clinical and economic evidence in R&D By Damian Garde   Kevin Lobo took the tob job at Stryker ($SYK) last month, and he said ...

Updated: Medtronic looks to unseat Edwards with heart valve

By Damian Garde Medtronic ($MDT) is inching toward European approval for its Engager heart valve, releasing data demonstrating the device to be safe and effective. Edwards Lifesciences ...

Allergan mulls sale of its anti-obesity device business

The news comes following setbacks in gaining expanded approval for Allergan’s Lap-Band device By Mark Hollmer Allergan ($AGN) may unload its anti-obesity device business, the ...

Cigarette maker Philip Morris rolls vaccine interests into China

By Ryan McBride Craving growth in the huge market for tobacco products in China, Philip Morris International ($PM) has invested in rights to flu vaccines made from a species of tobacco ...

Neuraltus Pharma eyes PhIII after missing endpoints in trial for ALS drug

By Ryan McBride Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig’s disease patients on its experimental ...

Theratechnologies once again tries to slash its way to breakeven point

By John Carroll Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability ...

Alzheimer’s investigators see fresh sign of solanezumab success in Eli Lilly study

By John Carroll Researchers took the center stage at an Alzheimer’s conference in Monaco to offer late-stage biomarker evidence to support Eli Lilly’s optimism about ...

Aveo slashes workforce, circles wagons around troubled kidney cancer drug

By John Carroll Struggling to overcome growing doubts about the future of its lead cancer drug, Cambridge, MA-based Aveo ($AVEO) this morning announced that it will shrink its workforce ...

Boehringer Ingelheim bets bigger on respiratory drugs

German drugmaker expanding inhaler plant for second time By Eric Palmer With respiratory drugs helping to fuel its earnings and new ones in the pipeline, Boehringer Ingelheim is ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS